ArticleTheranostics2021
Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Discovery of a potent and orally bioavailable type Ⅰ PRMTs inhibitor for triple-negative breast cancer treatment.Acta pharmacologica Sinica · 2026Article
- Structural landscape of H3K27me3 recognition by protein domains and their potential for inhibition.The Journal of biological chemistry · 2026Review
- Biological Evaluation of a Novel Compound with Predicted EZH2 and EED Binding Against Human Malignant Melanoma Cells.International journal of molecular sciences · 2026Article
- Method Development and Validation of Liquid Chromatography Tandem Mass Spectrometry for SLP-1A6 in Rat Plasma.Journal of chromatographic science · 2026Article
- Novel Skp1 inhibitor has potent preclinical efficacy against castration-resistant prostate cancer.British journal of cancer · 2025Article
- EZH2: From Oncogenic Driver to Therapeutic Target for Overcoming Drug Resistance in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2025Review
- Editorial: The emerging role of protein methylation/demethylation modification in disease and homeostasis.Frontiers in molecular biosciences · 2025Article
- Epigenetic and Cellular Reprogramming of Doxorubicin-Resistant MCF-7 Cells Treated with Curcumin.International journal of molecular sciences · 2024Article
- Targeting EED as a key PRC2 complex mediator toward novel epigenetic therapeutics.Drug discovery today · 2024Review
- Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation.Cancer metastasis reviews · 2024Review
- Therapeutic targeting potential of the protein lysine and arginine methyltransferases to reverse cancer chemoresistance.Frontiers in molecular biosciences · 2024Review
- Nicardipine is a putative EED inhibitor and has high selectivity and potency against chemoresistant prostate cancer in preclinical models.British journal of cancer · 2023Article
- Minor intron splicing is critical for survival of lethal prostate cancer.Molecular cell · 2023Article
- The roles of EZH2 in cancer and its inhibitors.Medical oncology (Northwood, London, England) · 2023Review
- Gli2-induced lncRNA Peg13 alleviates cerebral ischemia-reperfusion injury by suppressing Yy1 transcription in a PRC2 complex-dependent manner.Metabolic brain disease · 2023Article
- Gene-repressing epigenetic reader EED unexpectedly enhances cyclinD1 gene activation.Molecular therapy. Nucleic acids · 2023Article
- STAT3 pathway in cancers: Past, present, and future.MedComm · 2022Review
- From Therapy Resistance to Targeted Therapies in Prostate Cancer.Frontiers in oncology · 2022Review
- Measurement of Bone Metastatic Tumor Growth by a Tibial Tumorigenesis Assay.Bio-protocol · 2021Article
- Epithelial protein lost in neoplasm (EPLIN) and prostate cancer: lessons learned from the ARCaP model.American journal of clinical and experimental urology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 10 institutions in 3 countries.
Xin LiCenter for Cancer Research and Therapeutic Development and Department of Biological Sciences, Clark Atlanta University, Atlanta, GA, USA.
Lajos GeraDepartment of Biochemistry and Molecular Genetics, University of Colorado Denver, Anschutz Medical Campus, School of Medicine, Aurora, CO, USA.
Shumin ZhangDepartment of Urology and Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
Yanhua ChenMolecular Oncology and Biomarkers Program, Georgia Cancer Center; Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA, USA.
Lei LouSchool of Electrical and Computer Engineering, College of Engineering, University of Georgia, Athens, GA, USA.
Lauren Marie WilsonSchool of Electrical and Computer Engineering, College of Engineering, University of Georgia, Athens, GA, USA.
Zhong-Ru XieSchool of Electrical and Computer Engineering, College of Engineering, University of Georgia, Athens, GA, USA.
Giuseppe SauttoCenter for Vaccines and Immunology, University of Georgia, Athens, GA, USA.
Degang LiuSartorius Corporation, Bohemia, NY, USA.
Alira DanaherCenter for Cancer Research and Therapeutic Development and Department of Biological Sciences, Clark Atlanta University, Atlanta, GA, USA.
Kenza MamouniMolecular Oncology and Biomarkers Program, Georgia Cancer Center; Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA, USA.
Yang YangMolecular Oncology and Biomarkers Program, Georgia Cancer Center; Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA, USA.
Yuhong DuDepartment of Pharmacology and Chemical Biology, and Emory Chemical Biology Discovery Center, Emory University School of Medicine, Atlanta, GA, USA.
Haian FuDepartment of Pharmacology and Chemical Biology, and Emory Chemical Biology Discovery Center, Emory University School of Medicine, Atlanta, GA, USA.
Omer KucukDepartment of Urology and Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
Adeboye O OsunkoyaDepartment of Urology and Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
Jia ZhouChemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, USA.
Daqing WuCenter for Cancer Research and Therapeutic Development and Department of Biological Sciences, Clark Atlanta University, Atlanta, GA, USA.
Emory University · USUniversity of Georgia · USCenter for Cancer Research · USAugusta University Health · USClark Atlanta University · USMolecular Oncology (United States) · USSartorius (United Kingdom) · GBThe University of Texas Medical Branch at Galveston · USUnion Hospital · CNUniversity of Colorado Denver · US
Funding
To Investigate Molecular Mechanisms of Aging-Related Growth of the Prostate - Implications in Prostate Tumorigenesis and Cancer TreatmentU54MD007590 · NIMHD · CLARK ATLANTA UNIVERSITY · PI Geou-Yarh Liou · 2019 to 2026
$17.1MSmall-molecule therapy for metastatic castration-resistant prostate cancerR42CA217491 · NCI · METCURE THERAPEUTICS, LLC · PI WU, DAQING · 2021 to 2022
$1.9MNovel small-molecule targeted therapy for prostate cancerR41CA206725 · NCI · METCURE THERAPEUTICS, LLC · PI WU, DAQING · 2016 to 2016
$225kSmall-molecule therapy for metastatic prostate cancerR41CA217491 · NCI · METCURE THERAPEUTICS, LLC · PI WU, DAQING · 2017 to 2017
$225kA Dietary Supplement As Adjunct Therapy In Castration-Resistant Prostate CancerR41CA186498 · NCI · METCURE THERAPEUTICS, LLC · PI WU, DAQING · 2015 to 2015
$161kNCI NIH HHS R41 CA186498NCI NIH HHS R41 CA206725NCI NIH HHS R41 CA217491NCI NIH HHS R42 CA217491NIMHD NIH HHS U54 MD007590
Abstract
PubMed holds no abstract for this paper.
Indexed as
Drug Resistance, NeoplasmAnimalsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsATP Binding Cassette Transporter, Subfamily BBone NeoplasmsCell Line, TumorCell SurvivalDocetaxelDrug DiscoveryDrug SynergismEnhancer of Zeste Homolog 2 ProteinHumansInhibitory Concentration 50MaleMiceABCB1 protein, humanAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily BDocetaxelEED protein, humanEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanPolycomb Repressive Complex 2SKP2 protein, humanS-Phase Kinase-Associated ProteinsSTAT3 protein, humanSTAT3 Transcription FactorSurvivinchemoresistancedrug discoveryEED inhibitorEZH2 signalingprostate cancer
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.